Background
 PI3Kδ is highly expressed in cells of hematopoietic origin and is often upregulated in lymphoid malignancies  Umbralisib (TGR-1202, TGR) is a next generation PI3Kδ inhibitor, with a unique structure and activity profile distinct from other PI3Kδ inhibitors in development, including:
 Greater selectivity to the δ isoform of PI3K  A prolonged half-life that enables once-daily dosing  A differentiated safety profile from other PI3Kδ inhibitors, notably with respect to hepatic toxicity and colitis observed to date  Ublituximab (TG-1101, UTX) is a novel, chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen, and glycoengineered to enhance affinity for all variants of FcγRIIIa receptors, thereby demonstrating greater antibody-dependent cellular cytotoxicity (ADCC) activity than rituximab and ofatumumab.  Ublituximab is currently in Phase 3 development in combination with ibrutinib or TGR-1202 for patients with chronic lymphocytic leukemia (CLL), and in Phase 2b study for patients with Non-Hodgkin's Lymphoma (NHL). 
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Study Design
Key Eligibility Criteria Umbralisib (TGR-1202) Results † 9 Patients not evaluable: 7 too early to evaluate, 2 off prior to efficacy assessment (1 non-related AE, 1 investigator decision)
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Conclusions
 The non-chemotherapy doublet of ublituximab + TGR-1202 is a safe and efficacious backbone regimen on which to build novel multi-drug combinations  The combination of ublituximab + TGR-1202 + bendamustine is well tolerated and highly active in patients with advanced indolent and aggressive NHL, including those not eligible for HD/SCT or CD19 CART therapy, with: 
